LG-121071, formerly known as LGD-121071, is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally bioavailable nonsteroidal androgen to be discovered. It is a tricyclic quinolone analogue, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine). The drug acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM), with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT). References: Thevis M, Schanzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2017 Jan 27. pii: S0303-7207(17)30053-9. doi: 10.1016/j.mce.2017.01.040. [Epub ahead of print] PubMed PMID: 28137616.

纯度：≥98%

CAS：179897-70-2